Saracatinib trial TO Prevent FOP
The aim of this study is to investigate the efficacy and safety of the new drug AZD0530 (saracatinib) for treating patients with Fibrodysplasia Ossificans Progressiva (FOP). You can read more about FOP here. Beneath, you can find additional information about the study. If you have any additional questions after reading this information, please feel free to contact the researchers.
What participating means for you
Before you decide to participate or not, the research physisican will inform you extensively about what participating in the study means for you.
If you decide to participate, the study will last about one and a half years for you. During this period you will have to visit the hospital 10 times. During these visits several tests will be performed, these include blood draws and PET-CT scans.
Who can apply?
This study is performed in men and women with FOP between 18 and 65 years of age. A research physician will first determine if someone is eligible for the study. The research physician will perform several tests, ask about medical history and look at drug use.
The Saracatinib trial to prevent Fibrodysplasia Ossificans Progressiva (STOPFOP) will begin... read more
The STOPFOP team recently announced that enrollment for our clinical trial had started. Unfortunately... read more
The STOPFOP team is pleased to announce that ‘The Saracatinib trial to prevent Fibrodysplasia... read more
After overcoming several Omicron-variant related issues , STOPFOP site Klinikum Garmisch-... read more
We collaborate with members of patient organisations through our Stakeholders Board with members of: IFOPA and national FOP patient organisations from: The Netherlands, United Kingdom, Germany, France, Italy and Sweden.